Phio Pharmaceuticals Reports Positive PH-762 Skin Cancer Data
KING OF PRUSSIA, PENNSYLVANIA, March 23, 2026 Phio Pharmaceuticals Corp. has announced the presentation of positive clinical study results...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
KING OF PRUSSIA, PENNSYLVANIA, March 23, 2026 Phio Pharmaceuticals Corp. has announced the presentation of positive clinical study results...
March 06, 2026 — Wilmington, Delaware, USA Global biopharmaceutical innovator Incyte has announced that the European Commission has approved...
